ATE488236T1 - Verbindungen zur behandlung von dyslipidämie und anderer lipidstörungen - Google Patents

Verbindungen zur behandlung von dyslipidämie und anderer lipidstörungen

Info

Publication number
ATE488236T1
ATE488236T1 AT05796128T AT05796128T ATE488236T1 AT E488236 T1 ATE488236 T1 AT E488236T1 AT 05796128 T AT05796128 T AT 05796128T AT 05796128 T AT05796128 T AT 05796128T AT E488236 T1 ATE488236 T1 AT E488236T1
Authority
AT
Austria
Prior art keywords
compounds
dyslipidemia
treatment
lipid disorders
sequelae
Prior art date
Application number
AT05796128T
Other languages
English (en)
Inventor
James Dropinski
Guo Shi
Yong Zhang
Original Assignee
Merck Sharp & Dohme
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Sharp & Dohme filed Critical Merck Sharp & Dohme
Application granted granted Critical
Publication of ATE488236T1 publication Critical patent/ATE488236T1/de

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D261/00Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/20Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings condensed with carbocyclic rings or ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/06Antipsoriatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
AT05796128T 2004-09-16 2005-09-12 Verbindungen zur behandlung von dyslipidämie und anderer lipidstörungen ATE488236T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US61046604P 2004-09-16 2004-09-16
PCT/US2005/032557 WO2006033891A2 (en) 2004-09-16 2005-09-12 Compounds for the treatment of dyslipidemia and other lipid disorders

Publications (1)

Publication Number Publication Date
ATE488236T1 true ATE488236T1 (de) 2010-12-15

Family

ID=36090471

Family Applications (1)

Application Number Title Priority Date Filing Date
AT05796128T ATE488236T1 (de) 2004-09-16 2005-09-12 Verbindungen zur behandlung von dyslipidämie und anderer lipidstörungen

Country Status (9)

Country Link
US (1) US7629372B2 (de)
EP (1) EP1796665B1 (de)
JP (1) JP2008513458A (de)
CN (1) CN101027056A (de)
AT (1) ATE488236T1 (de)
AU (1) AU2005287215B2 (de)
CA (1) CA2581072A1 (de)
DE (1) DE602005024836D1 (de)
WO (1) WO2006033891A2 (de)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1861382B1 (de) * 2005-03-04 2012-10-10 Merck Sharp & Dohme Corp. Fusionierte aromatische verbindungen mit antidiabetischer wirkung
MX2008013237A (es) * 2006-04-14 2009-03-06 Merck & Co Inc Imidazol 4-caroxamidas sustituidas como moduladores del receptor colecistoquinina-1.
ITMI20062449A1 (it) * 2006-12-19 2008-06-20 Dipharma Spa Forma cristallina di rabeprazolo sodico
JP2010526807A (ja) 2007-05-07 2010-08-05 メルク・シャープ・エンド・ドーム・コーポレイション 抗糖尿病活性を有する縮合芳香族化合物を用いた治療法
ES2559238T3 (es) 2009-09-28 2016-02-11 Kowa Company, Ltd. Agente para reducir el peso de la grasa visceral
KR102098032B1 (ko) 2012-09-27 2020-04-07 교와 가부시키가이샤 지질 이상증 치료제
JPWO2015030033A1 (ja) 2013-08-28 2017-03-02 興和株式会社 脂質異常症治療剤
WO2015184375A2 (en) * 2014-05-29 2015-12-03 Whitehead Institute For Biomedical Research Compositions and methods for promoting intestinal stem cell and/or non-stem progenitor cell function

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH10502454A (ja) 1994-07-01 1998-03-03 リガンド・ファーマシューティカルズ・インコーポレーテッド Nuc阻害剤のスクリーニング
AU1856997A (en) 1996-02-02 1997-08-22 Merck & Co., Inc. Method for raising hdl cholesterol levels
ES2202582T3 (es) 1996-02-02 2004-04-01 MERCK & CO., INC. Agentes antidiabeticos.
JP2000504021A (ja) 1996-02-02 2000-04-04 メルク エンド カンパニー インコーポレーテッド 糖尿病及び関連疾患状態を治療する方法
WO1997027857A1 (en) 1996-02-02 1997-08-07 Merck & Co., Inc. Antidiabetic agents
WO1997028137A1 (en) 1996-02-02 1997-08-07 Merck & Co., Inc. Heterocyclic derivatives as antidiabetic and antiobesity agents
EP1259494A4 (de) * 2000-02-18 2004-09-15 Merck & Co Inc Aryloxyessigsäuren für diabetes und lipid-erkrankungen
US6569879B2 (en) * 2000-02-18 2003-05-27 Merck & Co., Inc. Aryloxyacetic acids for diabetes and lipid disorders
EP1347755A2 (de) * 2000-10-31 2003-10-01 Merck & Co., Inc. Benzopyrancarbonsäuren-derivate zur behandlung von diabetes und fettstörungen
US20040242459A1 (en) 2001-06-11 2004-12-02 Forrest Michael J Method for treating inflammatory diseases by administering a ppar-delta agonist
US7125865B2 (en) 2002-07-25 2006-10-24 Merck & Co., Inc. Therapeutic compounds for treating dyslipidemic conditions

Also Published As

Publication number Publication date
WO2006033891A2 (en) 2006-03-30
AU2005287215B2 (en) 2011-04-07
EP1796665A2 (de) 2007-06-20
CA2581072A1 (en) 2006-03-30
DE602005024836D1 (de) 2010-12-30
US20080039514A1 (en) 2008-02-14
EP1796665A4 (de) 2009-08-12
CN101027056A (zh) 2007-08-29
AU2005287215A1 (en) 2006-03-30
WO2006033891A3 (en) 2007-02-01
EP1796665B1 (de) 2010-11-17
JP2008513458A (ja) 2008-05-01
US7629372B2 (en) 2009-12-08

Similar Documents

Publication Publication Date Title
ATE488236T1 (de) Verbindungen zur behandlung von dyslipidämie und anderer lipidstörungen
PH12020500265A1 (en) Indole carboxamides compounds useful as kinase inhibitors
AU2013311573A8 (en) Methods of treating Alzheimer's disease and pharmaceutical compositions thereof
ATE390925T1 (de) Verwendung von substituierten chinolin-derivaten zur behandlung von arzneimittelresistenten mycobakteriellen erkrankungen
CY1116754T1 (el) Παραγωγα νιτροκατεχολης ως αναστολεις της comt
DE60322075D1 (de) Ppar alpha selektive verbindungen zur behandlung von dyslipidämie und anderen lipidstörungen
EA200701356A1 (ru) Ингибиторы транспорта глицина
UA100132C2 (en) Isoxazolo-pyridine derivatives
EA200701175A1 (ru) Лекарственные средства, предназначенные для лечения или предупреждения фиброзных заболеваний
ATE468851T1 (de) Ppar alpha selektive verbindungen zur behandlung von dyslipidämie und anderen lipidstörungen
UY27300A1 (es) Nuevos derivados de quinolina
ATE447551T1 (de) Biphenyloxyessigsäure - derivate zur behandlung von atemwegserkränkungen
DE602006007037D1 (de) Pyrrolotriazin-kinasehemmer
EA201300471A1 (ru) Замещенные 6-аминоникотинамиды в качестве модуляторов kcnq2/3
EA201491321A1 (ru) Фторметил-5,6-дигидро-4н-[1,3]оксазины
SE0401342D0 (sv) Therapeutic compounds
DK1853232T3 (da) Stabil krystallin form af bifeprunox mesylat, doseringsformer deraf og fremgangsmåder for deres anvendelse
TNSN07263A1 (en) Substituted 4-phenyl tetrahydroisoquinolines, methods for producing them, their use as drug, and drug containing them
DE60315479D1 (de) Pyrimidinamid derivate und deren verwendung
CY1116234T1 (el) Υποκατεστημενα 2-οξυ-κινολινο-3-καρβοξαμιδια σαν διαμορφωτες kcnq2/3
TW200732304A (en) Piperidine derivatives
DE602005015697D1 (de) Te zur behandlung von alzheimer-krankheit
CY1114760T1 (el) Θεραπευτικη αγωγη αθηροσκληρωσης
ATE432275T1 (de) Pyrrol- bzw. imidazolamide zur behandlung von obesitas
EA200701813A1 (ru) Новые амидозамещенные 6-фенилфенантридины

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties